Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) Cash & Equivalents (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Cash & Equivalents for 5 consecutive years, with $20.2 million as the latest value for Q3 2020.

  • Quarterly Cash & Equivalents fell 21.13% to $20.2 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $20.2 million through Sep 2020, down 21.13% year-over-year, with the annual reading at $6.9 million for FY2019, 83.0% down from the prior year.
  • Cash & Equivalents for Q3 2020 was $20.2 million at Forte Biosciences, down from $27.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $76.1 million in Q2 2017, with the low at $4.1 million in Q3 2016.
  • Average Cash & Equivalents over 5 years is $24.5 million, with a median of $20.2 million recorded in 2020.
  • The sharpest move saw Cash & Equivalents soared 1730.77% in 2017, then crashed 83.0% in 2019.
  • Over 5 years, Cash & Equivalents stood at $5.5 million in 2016, then skyrocketed by 552.14% to $35.9 million in 2017, then increased by 13.58% to $40.8 million in 2018, then plummeted by 83.0% to $6.9 million in 2019, then skyrocketed by 190.75% to $20.2 million in 2020.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $20.2 million, $27.7 million, and $14.2 million for Q3 2020, Q2 2020, and Q1 2020 respectively.